Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30066703 | 1.00 | CRBN (0.45) | CRBNDDB1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25219414 | 0.91 | CRBN (0.49) | CRBNDDB1POLB | |
| SCHEMBL31306892 | 0.90 | CRBN (0.47) | CRBNDDB1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31470530 | 0.82 | CRBN (0.44) | CRBNDDB1POLB | |
| SCHEMBL29990395 | 0.82 | CRBN (0.63) | CRBNDDB1POLB | |
| SCHEMBL24881033 | 0.82 | CRBN (0.63) | CRBNDDB1POLB | |
| SCHEMBL25074521 | 0.82 | CRBN (0.63) | CRBNDDB1POLB | |
| SCHEMBL29208470 | 0.82 | CRBN (0.63) | CRBNDDB1POLB | |
| SCHEMBL31470511 | 0.81 | CRBN (0.43) | CRBNDDB1POLB | |
| Hydrochloric Acid SCHEMBL29220529 | 0.81 | CRBN (0.61) | CRBNDDB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |